194 related articles for article (PubMed ID: 27423119)
1. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
3. Discovery of thiazolidin-4-one analogue as selective GSK-3β inhibitor through structure based virtual screening.
Choudhary BS; Sukanya ; Mehta P; Bach S; Ruchaud S; Robert T; Josselin B; Filipek S; Malik R
Bioorg Med Chem Lett; 2021 Nov; 52():128375. PubMed ID: 34560262
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β.
Yang Z; Liu H; Pan B; He F; Pan Z
Org Biomol Chem; 2018 Jun; 16(22):4127-4140. PubMed ID: 29781013
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors.
Zhou Y; Zhang L; Fu X; Jiang Z; Tong R; Shi J; Li J; Zhong L
Chem Biodivers; 2019 Sep; 16(9):e1900304. PubMed ID: 31338947
[TBL] [Abstract][Full Text] [Related]
9. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
[TBL] [Abstract][Full Text] [Related]
11. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
[TBL] [Abstract][Full Text] [Related]
13. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
14. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
15. First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents.
Brogi S; Ramunno A; Savi L; Chemi G; Alfano G; Pecorelli A; Pambianchi E; Galatello P; Compagnoni G; Focher F; Biamonti G; Valacchi G; Butini S; Gemma S; Campiani G; Brindisi M
Eur J Med Chem; 2017 Sep; 138():438-457. PubMed ID: 28689095
[TBL] [Abstract][Full Text] [Related]
16. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Kohara T; Nakayama K; Watanabe K; Kusaka SI; Sakai D; Tanaka H; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Mori A; Tanaka S; Bessho T; Takiguchi-Hayashi K; Horikawa T
Bioorg Med Chem Lett; 2017 Aug; 27(16):3733-3738. PubMed ID: 28712706
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
Khan I; Tantray MA; Hamid H; Alam MS; Kalam A; Hussain F; Dhulap A
Bioorg Chem; 2016 Oct; 68():41-55. PubMed ID: 27454617
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel 4,5-bisindolyl-1,2,4-triazol-3-ones as glycogen synthase kinase-3β inhibitors and neuroprotective agents.
Hu Y; Ruan W; Gao A; Zhou Y; Gao L; Xu M; Gao J; Ye Q; Li J; Pang T
Pharmazie; 2017 Dec; 72(12):707-713. PubMed ID: 29441954
[TBL] [Abstract][Full Text] [Related]
20. Biological evaluation and energetic analyses of novel GSK-3β inhibitors.
Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X
J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
